New pharmacological directions for the treatment of overweight and obesity.
作者信息
Van Gaal L F, Peiffer F W, De Leeuw I H
机构信息
Dept. of Endocrinology, Metabolism and Clinical Nutrition, University Hospital Antwerp, Belgium.
出版信息
Acta Clin Belg. 1999 Jun;54(3):141-6. doi: 10.1080/17843286.1999.11754219.
Abstract
摘要
相似文献
1
New pharmacological directions for the treatment of overweight and obesity.
Acta Clin Belg. 1999 Jun;54(3):141-6. doi: 10.1080/17843286.1999.11754219.
2
[Obesity in adults].
Praxis (Bern 1994). 2007 Oct 17;96(42):1617-24; quiz 1625-6. doi: 10.1024/1661-8157.96.42.1617.
3
[Pharmacotherapy of obesity].
Ugeskr Laeger. 2004 Oct 18;166(43):3814-7.
4
[Pharmacotherapy in the treatment of obesity].
MMW Fortschr Med. 2006 Mar 2;148(9):36-8. doi: 10.1007/BF03364581.
5
[Anti-obesity drugs: sibutramine and orlistat].
Med Clin (Barc). 2002 Mar 30;118(11):437; author reply 437-8. doi: 10.1016/s0025-7753(02)72409-3.
6
[Pharmacological therapy of obesity].
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
7
Orlistat for obesity.
Med Lett Drugs Ther. 1999 Jun 18;41(1055):55-6.
8
Obesity, cardiovascular risk and pharmacotherapy.
Blood Press. 2002;11(5):260-2. doi: 10.1080/080370502320779458.
9
[Drug treatment of obesity].
Ugeskr Laeger. 2006 Jan 9;168(2):163-7.
10
Long-term pharmacotherapy for obesity and overweight.
Cochrane Database Syst Rev. 2003(4):CD004094. doi: 10.1002/14651858.CD004094.
Zotero 插件